ABBOTINDIA.NS
ABBOTINDIA.NS
INE358A01014
ABBOTT INDIA LIMITED
Loading chart...

Company Profile

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory, hepatic, neuroscience, metabolics, gennext, and consumer care products. The company was formerly known as Knoll Pharmaceuticals Limited and changed its name to Abbott India Limited in July 2002. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited operates as a subsidiary of Abbott Capital India Limited.

Related stocks

IPCALAB.NS
IPCALAB.NS • India
IPCA LABORATORIES LTD
1,915.4 INR
5.02B USD 1Y +43%
GLENMARK.NS
GLENMARK.NS • India
GLENMARK PHARMACEUTICALS
2,293 INR
6.69B USD 1Y +13.6%
ALKEM.NS
ALKEM.NS • India
ALKEM LABORATORIES LTD.
5,279 INR
6.52B USD 1Y -4.4%
AJANTPHARM.NS
AJANTPHARM.NS • India
AJANTA PHARMA LIMITED
3,410.1 INR
4.4B USD 1Y +40.8%
AUROPHARMA.NS
AUROPHARMA.NS • India
AUROBINDO PHARMA LTD
1,693 INR
10.07B USD 1Y +51.2%
LUPIN.NS
LUPIN.NS • India
LUPIN LIMITED
1,956.5 INR
9.24B USD 1Y -0.1%
EMCURE.NS
EMCURE.NS • India
EMCURE PHARMACEUTICALS L
1,833.5 INR
3.59B USD 1Y +31.4%
CIPLA.NS
CIPLA.NS • India
CIPLA LTD
1,301 INR
10.86B USD 1Y -14%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

6/7 High
5Y Volatility
22.6% p.a.
Max Drawdown (5Y)
-29.4%
Sharpe Ratio (5Y)
0.03
Beta Factor
0.06
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende